Document is current
Any future updates will be listed below
-
Authors
Young, Lisa https://orcid.org/0000-0001-7988-9161
Chen, Yong
Alvir, José
Burke, Tom https://orcid.org/0000-0001-6768-1670
Ferri Grazzi, Enrico https://orcid.org/0000-0002-0567-0260
Winburn, Ian https://orcid.org/0000-0002-6357-2642
-
Funding
Funding for this research was provided by:
Pfizer (Pfizer)
- License Information
-
More Information
Article History
Received: 12 December 2022
Accepted: 2 April 2023
First Online: 3 August 2023
Declarations
:
: YC, JA, and IW are employees of Pfizer and may own stock/options in the company. LY was an employee of Pfizer at the time of this analysis and may own stock/options in the company. TB and EFG are employees of HCD Economics, which received funding from Pfizer for research conducted in this study.
: CHESS II was approved by the University of Chester Ethics Committee. It was conducted in collaboration with the UK Haemophilia Society and in correspondence with regional and relevant guidelines. The study was governed by a steering committee chaired by Brian O’Mahony, Chief Executive of the Irish Haemophilia Society. Patient consent was obtained via tick box selection for the patient-reported element of the study.
: Not applicable.
